Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.40 |
| ▸ | MAOA | P21397 | 15/20 | 0.40 |
| ▸ | MAOB | P27338 | 15/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31560811 | 0.76 | MAOB (0.41) | KDM1AMAOAMAOBTSHRCYP2C19 | |
| SCHEMBL1854233 | 0.75 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL25339542 | 0.67 | KDM1A (0.61) | KDM1AMAOAMAOB | |
| SCHEMBL8845605 | 0.64 | HTR2C (0.41) | KDM1AMAOAMAOBTSHRCYP2C19 | |
| SCHEMBL8845602 | 0.64 | HTR2C (0.41) | KDM1AMAOAMAOBTSHRCYP2C19 | |
| SCHEMBL4331068 | 0.60 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL12946117 | 0.60 | KDM1A (0.67) | KDM1AMAOAMAOB | |
| SCHEMBL18298261 | 0.60 | TSHR (0.39) | KDM1AMAOAMAOBTSHRCYP2C19 | |
| SCHEMBL1274251 | 0.60 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL1415636 | 0.60 | KDM1A (0.54) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | KDM1A 2074/4885MAOA 3640/4885MAOB 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.